Undisclosed antibody-drug conjugate - AbbVie/Seattle Genetics

Drug Profile

Undisclosed antibody-drug conjugate - AbbVie/Seattle Genetics

Alternative Names: Undisclosed ADC - Abbvie/Seattle Genetics

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator AbbVie; Seattle Genetics
  • Class Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 30 Jul 2015 Phase-I clinical trials in Haematological malignancies in USA (Parenteral)
  • 23 Mar 2011 Preclinical trials in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top